Twitter Facebook-f Youtube Instagram Linkedin
NETs Info
Donate
Close Menu
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • Research Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • NET National Action Plan
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Bequests
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us
Donate
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • Research Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • NET National Action Plan
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Bequests
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us

Home » Research » Financial Impact Study

Financial Impact Study

  • December 20, 2017
Financial Impact Study – Living with NETs 

Research is vital in improving outcomes for people affected by NETs.

The Unicorn Foundation is always striving to provide opportunities for NET patients to have their say on a range of important issues, and is very pleased to invite you to take part in a study exploring the financial impacts of NeuroEndocrine Tumours (NETs).

Why is the research being conducted?
The purpose of the study is to understand the financial outcomes, and potential burden, for people living with NETs. Families experiencing ongoing follow-up and symptom management of NET cancer can face significant personal medical expenses and time off work. This research will enable researchers to improve awareness of NETs in the medical profession, the general public and most importantly with policy makers. We will be able to demonstrate the financial burden of patients with NETs and we will seek to understand and quantify this issue. 

Who is running the project? 
Medical oncologists from Brisbane (A/Prof David Wyld), Melbourne (A/Prof Michael Michael), and Sydney (A/Prof Nick Pavlakis), health economics researcher (A/Prof Louisa Gordon), the Unicorn Foundation (Kate Wakelin, Dr John Leyden, Simone Leyden) and Australian Gastro-Intestinal Trials Group (Jan Mumford), with more hospitals to come online in the future.

Who can participate? 
Patients with Grade 1 or 2 NETs and are over 18 years of age. Unfortunately patients with phaeochromocytomas/paragangliomas are ineligible to participate at this stage.
What will I be asked to do? Participation is entirely voluntary. The survey can be completed separate to providing consent for Medicare records. Please note that the survey could take up to 20-30 mins, so grab a cup of tea, and know that your contribution is making a difference for the future.

You will be asked to…..
Step 1: complete a one-off 20-30 minute survey. The survey is online and can be completed here : https://labportal.qimr.edu.au/s/3vem

Step 2: provide your consent to release your Medicare records to the researchers (please email netnurse@neuroendocrine.org.au to have this form mailed to you) 

What if I have questions? 
Please contact Louisa Gordon (07) 3845 3717/ louisa.gordon@qimrberghofer.edu.au, or Kate Wakelin (1300 287 363/ netnurse@neuroendocrine.org.au) if you have any questions.

Has this research been approved by an ethics committee? 
Yes, the QIMR Berghofer Medical Research Institute Human Research Ethics Committee and the other hospital site ethics committees have approved this study.
We strongly encourage everyone affected by NETs, who meet the above eligibility, to take part in this important research.       

Share this post

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

5HIAA Urine Collection Instructions for Patients

June 23, 2022

Donor Report 2021/2022

June 21, 2022

Cancer Nurses Society of Australia 24th Annual Congress

June 18, 2022

The Future of Precision Oncology in Nuclear Medicine – Report

June 16, 2022
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousSelect Committee Report – Funding for Research for Low Survival Cancers
NextNutrition in NET surveyNext

Related Posts

5HIAA Urine Collection Instructions for Patients

Your doctor may order you to do a 5HIAA 24 hour urine test. Please click below to see the downloadable instruction sheet. Previously there were

Donor Report 2021/2022

It is with heartfelt gratitude that we thank our kind donors who enable us to continue to do what we do. We encourage you to

Cancer Nurses Society of Australia 24th Annual Congress

The 24th Cancer Nurses Society of Australia’s  (CNSA) Annual Congress took place at Brisbane Convention Centre Thursday 16 June to Saturday 18 June 2022. The

The Future of Precision Oncology in Nuclear Medicine – Report

Theranostics refers to a combined therapy and diagnostics approach to patient treatment. It involves the use of a diagnostic drug to first identify and label

View All

Make a difference

How much do you wish to donate?
$50
$100
$250
$500
$1000
Other
NeuroEndocrine Cancer Australia logo white
Twitter Facebook-f Youtube Instagram Linkedin

All donations are tax deductible.
Registered Charity CFN 202607

Who We Are

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • Research Advisory Panel
  • Governance & Policies
Menu
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • Research Advisory Panel
  • Governance & Policies

Neuroendocrine Cancers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
Menu
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

For Patients

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
Menu
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
Menu
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise

© 2020 NeuroEndocrine Cancer Australia

  • Website by Five Creative